OpenEvidence, an AI search engine for doctors, has raised $250 million in Series D funding at a $12 billion valuation.
The new investment doubles OpenEvidence’s valuation in just three months, underscoring that as competition intensifies, the premiums investors are willing to pay for a slice of these AI companies are going up.
“The valuation suggests a business model well beyond selling ads to doctors’ eyeballs and more in line with the company’s pursuit of medical superintelligence,” said Brian Wright, PitchBook’s lead healthcare research analyst. “The race is on.”
Dubbed the “ChatGPT for doctors,” OpenEvidence’s AI models have been trained solely on medical journals and data, according to the company. It has also expanded its product with features such as an agentic research assistant tool and medical scribing.
Even the largest LLM makers have jumped into healthcare, with OpenAI, Anthropic and Google unveiling related products earlier this month in time for JP Morgan’s annual healthcare conference.
Thrive Capital and DST Global led this latest funding round. In October 2025, OpenEvidence raised a $200 million Series C at a $6 billion valuation, just three months after raising its Series B round at $3.5 billion.
Median valuation step-ups for AI companies overall are running ahead of non-AI startups, according to PitchBook data.
In increasingly crowded fields, beyond healthcare, valuation growth for AI startups is accelerating. Parloa, a startup developing AI agents for customer service, recently nearly tripled its valuation after raising a $350 million Series D. Legora, an AI legaltech startup, more than doubled its valuation after raising a $150 million Series C in October, five months after its last round.
In the case of OpenEvidence, investors see plenty of investment upside in the race to medical superintelligence—even if it means paying a premium to get on the rocket ship.
“Big-time [total addressable market], big-time competition,” Wright said.
Learn about our editorial standards.